On October 8, 2026 Thyme Companies, a family of businesses purpose-built to solve problems across the cancer care landscape, reported the launch of Thyme Therapeutics, a new business focused on driving reductions in the cost of oncology drugs. The company will work closely with oncologists, health plans, and manufacturers to commercialize oncology biosimilars. Its model will help patients access more affordable care, make lower-cost treatments easier for oncologists to adopt, and reduce overall healthcare costs.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Biosimilars have already offered promising saving opportunities in cancer care, but unstable prices and other market dynamics have limited those savings. Even when lower-cost options are covered and prescribed, pricing can shift significantly from quarter to quarter, keeping drug spend high and unpredictable. Thyme Therapeutics is built to align incentives across manufacturers, payers, and providers so the savings from lower-cost biosimilars reach patients and hold up over time.
"Few challenges in oncology are more urgent to solve right now than the rising cost of cancer drugs," said Robin Shah, executive chairman of Thyme Companies. "With Thyme Therapeutics, we have an opportunity to rethink how value moves through the system so that more of the savings created by biosimilars can ultimately benefit patients and the healthcare system as a whole."
Thyme Therapeutics plans to launch its first asset in 2027 and is actively engaging leading oncology groups, biosimilar manufacturers, and health plans as it builds its initial portfolio. Thyme Therapeutics will build on Thyme Care’s mission to transform cancer care in a way that reduces costs for patients in partnership with both payers and providers as it works to bring additional biosimilars to market.
This launch comes at a critical inflection point for cancer care. U.S. oncology drug spending reached approximately $84 billion in 2025, an increase of roughly 20% in a single year, while several of the industry’s highest-cost cancer therapies are approaching loss of exclusivity. That opportunity could meaningfully reset the economics of cancer care, but only if lower-cost products achieve broad and sustained adoption. Thyme Therapeutics was built to help turn that opportunity into more predictable, durable savings.
Thyme Therapeutics is the first new business launched by Thyme Companies following its formation in September 2026, alongside its Series E financing, and will initially focus on biosimilar medications. Thyme Companies was established to build independent businesses that address distinct challenges across the cancer care ecosystem, with Thyme Therapeutics as the next such business alongside Thyme Companies’ first venture, Thyme Care. To learn more about the company and the team, visit thymetherapeutics.com.